Ophthalmology and Therapy最新文献

{"title":"Silicone Oil Removal With or Without Air-Fluid Exchange: A Retrospective Comparative Study.","authors":"Xin Liu, Meng-Meng Ji, Ling Jin, Ai-Ping Zeng","doi":"10.1007/s40123-025-01193-0","DOIUrl":"10.1007/s40123-025-01193-0","url":null,"abstract":"<p><strong>Introduction: </strong>To evaluate whether the air-fluid (A-F) exchange procedure should be recommended for silicone oil (SO) removal surgery.</p><p><strong>Methods: </strong>Consecutive patients that underwent SO removal with or without A-F exchange were requested to complete a questionnaire regarding the presence of floaters and SO residual scores. The medical records of the patients who completed the questionnaire were also reviewed retrospectively for clinical data including best corrected visual acuity, postoperative detachment rate, and intraocular pressure, etc. RESULTS: A total of 124 cases were included, 68 in the A-F (+) group and 56 in the A-F (-). Both groups were similar in demographic data such as age, sex distribution, axial length, and duration of SO tamponade (all P > 0.05). During the process of A-F exchange, a layer of oil film residue can be observed under the microscope, and A-F exchange can remove the residual SO. The ratio of with/without floating in the A-F (-) versus A-F (+) group was 48/8 versus 36/32 (P < 0.01). In addition, the questionnaire survey on the SO residual scores showed a more significant difference in the impact on postoperative visual quality between the two groups.</p><p><strong>Conclusions: </strong>A-F exchange can effectively reduce residual SO and is recommended as a routine procedure for SO removal surgery.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2021-2029"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Repeated Low-Level Red Light Versus 0.01% Atropine Treatment on Axial Length and Choroidal Parameters in Children with Myopia.","authors":"Xuena Pang, Aicun Fu, Guangying Zheng, Weiqun Wang, Mei Zhong, Lili Shang, Minghang Chang, Xuemin Jin","doi":"10.1007/s40123-025-01169-0","DOIUrl":"10.1007/s40123-025-01169-0","url":null,"abstract":"<p><strong>Introduction: </strong>This research was designed to compare the effectiveness of repeated low-level red light (RLRL) and 0.01% atropine on axial length (AL), spherical equivalent refraction (SER), and choroidal parameters in children with myopia.</p><p><strong>Methods: </strong>We conducted a prospective, randomized, and single-blind controlled trial. Ninety-one children aged 6-12 years old were selected, with cycloplegic SER ≥ - 5.00 D and ≤ - 0.75 D. Participants were randomly assigned to the RLRL group and 0.01% atropine group. The primary outcomes included changes in AL, SER, and choroidal parameters after a duration of 6 months. Choroidal parameters specifically including the foveal, parafoveal, and perifoveal choroidal thickness (ChT) and the foveal, parafoveal, and perifoveal choroidal vessel volume (CVV).</p><p><strong>Results: </strong>At 6-month follow-up, the AL and SER changes were - 0.09 mm (- 0.18, 0.01) compared to 0.13 mm (0.05, 0.24) (p < 0.001) and 0.25 D (0, 0.50) compared to - 0.25 D (- 0.53, 0) (p < 0.001) in the RLRL and 0.01% atropine groups. The foveal, parafoveal and perifoveal ChT changes were 36.38 µm (14.05, 65.39), 31.04 µm (4.09, 59.35), and 28.48 µm (5.35, 55.15), compared to 0.94 µm (- 9.20, 9.36), 3.52 µm (- 10.24, 14.45), and 6.14 µm (- 5.21, 15.69) (all p < 0.001) in the RLRL and 0.01% atropine groups. The foveal, parafoveal, and perifoveal CVV changes were 0.01 μm³ (0.00, 0.02), 0.05 μm³ (0.02, 0.09), and 0.20 μm³ (0.05, 0.30) compared to 0.00 μm³ (- 0.00, 0.01), 0.01 μm³ (- 0.02, 0.03), and 0.01 μm³ (- 0.06, 0.09) (p < 0.001) in the corresponding two groups.</p><p><strong>Conclusions: </strong>After 6 months of treatment, RLRL was more effective than 0.01% atropine in controlling axial elongation and myopic progression among children with myopia. The foveal, parafoveal, and perifoveal ChT and foveal, parafoveal, and perifoveal CVV changes in the RLRL group were significantly higher than those in the 0.01% atropine group.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"1739-1754"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of a Viscous Cysteamine Eyedrop in a Belgian Cohort: Early 3-Year Results.","authors":"Emiel Matthys, Heleen Delbeke, Karel Van Keer, Ingele Casteels","doi":"10.1007/s40123-025-01170-7","DOIUrl":"10.1007/s40123-025-01170-7","url":null,"abstract":"<p><strong>Introduction: </strong>With the life expectancy of patients with cystinosis increasing (ORPHA213), the corneal burden and the objective assessment of corneal crystal deposition have become increasingly important. Previous research highlights the disadvantages of hospital-prepared cysteamine solutions (HPCS), including limited efficacy, which can lead to visual decline. Cystadrops^® is a viscous topical treatment in cystinosis care that counteracts these disadvantages.</p><p><strong>Methods: </strong>A total of 14 patients with cystinosis and corneal involvement are being followed in the multidisciplinary cystinosis clinic of the University Hospital of Leuven. Data retrieved between September 2014 and March 2023 were analyzed. All patients were initially treated with HPCS before switching to Cystadrops^®. Patients were assessed yearly according to the standard clinical ophthalmological examination for patients with cystinosis developed by Pinxten et al. Photophobia, corneal crystal deposition, and corneal crystal deposition depth were measured by the Liang cystinosis photophobia score, Gahl score, and anterior segment optical coherence tomography (OCT) respectively. Corneal densitometry was assessed with Scheimpflug imaging.</p><p><strong>Results: </strong>OCT mean crystal depth was 83% of total corneal thickness. The mean corneal density was 28.9 grayscale units. We found a positive trend (F = 0.20, p = 0.65) in corneal densitometry despite the use of HPCS, with a decreasing trend (F = 3.30, p = 0.08) after switching to Cystadrops^®. Photophobia scores significantly reduced after switching treatments (p = 0.008). In total, seven patients developed anterior segment complications while using HPCS. No new anterior segment complications developed while using Cystadrops^®.</p><p><strong>Conclusions: </strong>This study underscores previous research, demonstrating HPCS' limited effectiveness in reducing corneal crystal deposition due to unachievable dosing frequencies and poor stability. Our data highlights the effectiveness of Cystadrops^® in treating the ocular symptoms of cystinosis. The data demonstrates the difficulty of reversing high levels of corneal crystal deposition and anterior segment complications. Starting Cystadrops^® early in the disease course may prevent high rates of crystal deposition, thus reducing complications and their impact on vision and quality of life.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2043-2053"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Trial Simulation in Geographic Atrophy: Patient, Caregiver, and Trial Site Staff Perspectives.","authors":"Ivana Gunderson, Asma Burale, Bill J Best, Cynthia I Tung, Jochen Huber, Lisa Marsh","doi":"10.1007/s40123-025-01188-x","DOIUrl":"10.1007/s40123-025-01188-x","url":null,"abstract":"<p><strong>Introduction: </strong>The perspectives of patients with geographic atrophy (GA) should be considered when planning new clinical trials to ensure that real-world patient needs are addressed. The purpose of this study was to explore the perspectives of patients, caregivers, and trial site staff on designing and planning a phase 2 clinical trial in GA.</p><p><strong>Methods: </strong>This cross-sectional study included patients with GA and their caregivers, trial site staff, and investigators from Germany, the UK, and the USA. Participants were asked to spend 30 min reviewing a simulated trial design communicated as a simple video animation with a voiceover. Subsequently, a 90-min web-assisted telephone interview and survey was conducted to identify problems with the design of the simulated trial and explore potential solutions and improvements.</p><p><strong>Results: </strong>Patients (n = 11), caregivers (n = 11), and site staff (n = 16) completed the survey after reviewing the simulated trial design. Survey responses suggested that study recruitment could be facilitated via widespread advertisement and by including a short washout period, i.e., the time period during which patients receive no medication prior to commencing the study drug to ensure that other treatments do not impact the study results. Survey suggestions for reducing the burden of trial participation included minimizing the number and frequency of trial visits, enabling assessments to be completed at home, and making the schedule of trial visits flexible. Appropriate investment in study center facilities was recommended. In addition, survey respondents proposed that providing transport could be highly beneficial, potentially enabling patients and caregivers to attend trial visits more easily.</p><p><strong>Conclusions: </strong>This study provides valuable information on the viewpoints of patients, caregivers, and trial site staff regarding trial design. Accounting for these perspectives when designing future clinical trials may help ensure successful trial completion and promote positive perceptions of clinical research.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"1855-1868"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in Acute Ocular Surface Chemical Injury-Role of pH Measurement on Presentation: A Retrospective Cohort Study.","authors":"Emma Spowart, Sayali Pradhan, Charlotte Bruce, Borja Salvador-Culla, Gustavo Figueiredo, Francisco C Figueiredo","doi":"10.1007/s40123-025-01155-6","DOIUrl":"10.1007/s40123-025-01155-6","url":null,"abstract":"<p><strong>Introduction: </strong>Chemical eye injury is an ophthalmic emergency which can lead to loss of vision. We aimed to determine the prognostic value of tear film pH on presentation in acute chemical eye injuries.</p><p><strong>Methods: </strong>Demographics, pH values, causative chemical, injury circumstances, injury severity, and clinical and visual outcomes were assessed from previously collated data from patients presenting to the emergency eye department (EED) in a UK tertiary hospital. All patients who had pH measured before irrigation in the EED were included. Associations with injury severity and clinical and visual outcomes were analysed.</p><p><strong>Results: </strong>Pre-irrigation pH was recorded in 135 eyes (113 patients, 66.4% male, mean age 35.5 years [range 2-78; standard deviation (SD) 15.4]; 15 acid, 108 alkali, 12 unknown). The pH within 24 h of injury (n = 108 eyes) correlated significantly with injury severity (r_s = 0.20, p = 0.02). In patients with abnormal pH on presentation (n = 26 eyes), pH correlated strongly with injury severity (r_s = 0.72, p < 0.01). There was no significant correlation with visual outcome at follow-up (n = 70 eyes, 60 patients, follow-up 1-3929 days, mean 579.4 days, SD 1206.0 days; r_s = 0.12, p = 0.11). Presenting pH below 6.5 or above 7.5 was a significant predictive factor for the presence of limbal stem cell deficiency (LSCD) (univariate binary logistic regression analysis, p = 0.026, Nagelkerke R-squared = 0.090).</p><p><strong>Conclusion: </strong>Deranged pH correlated with burn severity in patients presenting within 24 h of injury and was a significant predictive factor for LSCD.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"1713-1722"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical Techniques for Cosmetic Eye Color Change: A Narrative Review.","authors":"Francesco D'Oria, Jorge L Alio","doi":"10.1007/s40123-025-01177-0","DOIUrl":"10.1007/s40123-025-01177-0","url":null,"abstract":"<p><p>The desire for permanent cosmetic change of eye color has driven the development of various surgical techniques aimed at achieving this transformation, pursuing more enduring solutions. This demand has led to the emergence of three primary surgical approaches: cosmetic iris implants, laser iris depigmentation, and cosmetic keratopigmentation (KTP). Each technique presents distinct advantages, yet also entails specific limitations and potential risks. Cosmetic iris implants, originally designed for congenital or traumatic iris defects, have been repurposed for aesthetic use. However, they come with severe risks, including glaucoma, corneal endothelial cell loss, and even permanent vision impairment. As a result of these complications, they are not approved by major regulatory bodies and are widely considered unsafe. Laser iris depigmentation offers a less invasive approach, using a Q-switched Nd:YAG laser to remove melanin from the anterior iris stroma. While it provides a natural-looking result, it lacks customization and has potential complications like patchy pigmentation, photophobia, and temporary intraocular pressure spikes. Additionally, there is limited long-term data on its safety. Cosmetic KTP, an advanced version of corneal tattooing, has emerged as the safest and most effective option. It involves embedding micronized mineral pigments into the cornea, allowing for precise, customizable, and long-lasting results. Studies show high patient satisfaction and minimal risks when properly performed. Among these techniques, KTP appears to be the best choice owing to its safety and aesthetic flexibility, while cosmetic iris implants should be avoided because of their high risk of complications, and laser iris depigmentation deals with limitations in color selection and long-term reliability. While KTP currently seems the safest option for cosmetic eye color change, this is largely based on limited single-center data and should be confirmed by larger studies in the future.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"1685-1694"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Eyesi Slit Lamp Simulator for a Simulated Training Curriculum for Residents in Ophthalmology: A National Delphi study.","authors":"Kasper Ruotsalainen Hansen, Simon Joel Lowater, Kristina Sanne Lyngsø, Anne Helene Køllund Nissen, Anna Stage Vergmann","doi":"10.1007/s40123-025-01175-2","DOIUrl":"10.1007/s40123-025-01175-2","url":null,"abstract":"<p><strong>Introduction: </strong>Simulation-based training is increasingly used in medical education to improve clinical skills. The Eyesi slit lamp simulator offers a platform for training in slit lamp examination and indirect ophthalmoscopy. However, training needs to be evidence-based to ensure reliable evaluation. Therefore, this study aims to identify relevant training modules on the Eyesi slit lamp simulator for ophthalmology residents through a national Delphi study to develop a training curriculum.</p><p><strong>Methods: </strong>A two-round Delphi study was conducted with chief physicians, consultants, and professors involved in ophthalmology residency training across Denmark. In round one, experts evaluated the relevance of training modules on the Eyesi slit lamp simulator using a binary scale, and modules achieving ≥ 75% in relevance were included in round two. In round two, these modules were rated on a linear scale (1-5) for detailed assessment. Consensus was defined by a standard deviation (SD) < 1.0 and interquartile ranges (IQR) were calculated to assess variability and identify outliers.</p><p><strong>Results: </strong>A total of 11 experts participated in round one (response rate: 84.6%), and 8 experts participated in round two (response rate: 72.7%). In round one, a strong expert agreement on module relevance was found. In round two, all modules achieved a mean ranking > 3.0, with the lowest being 3.9. Modules with a mean ranking > 3.0 were considered relevant and included in the final analysis. Two modules had an SD > 1.0, indicating a lack of consensus.</p><p><strong>Conclusions: </strong>This study established expert consensus on 32 essential training modules for the Eyesi slit lamp simulator, supporting their integration into an ophthalmology residency curriculum. Further testing under an evidence-based framework is required to integrate them into a structured curriculum and assess their impact on clinical skills.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"1999-2020"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety Evaluation of Bilateral Same-Day Intravitreal Injection of Faricimab.","authors":"Michael D Karampelas, Irini P Chatziralli, Dimitrios A Karagiannis","doi":"10.1007/s40123-025-01184-1","DOIUrl":"10.1007/s40123-025-01184-1","url":null,"abstract":"<p><strong>Introduction: </strong>Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is the most commonly performed ophthalmic procedure. Many retinal specialists routinely perform same-day bilateral intravitreal anti-VEGF injections, in order to reduce the burden to patient and clinic time. There are several reports demonstrating the safety of bilateral same-day treatment with ranibizumab, bevacizumab, and aflibercept, but currently, there are no reports regarding faricimab. The purpose of this study is to report safety outcomes in a cohort of patients who received bilateral same-day faricimab intravitreal injections.</p><p><strong>Methods: </strong>This is a retrospective observational study that included patients who received bilateral same-day faricimab and had a follow-up of at least 6 months. All patients were treated by 4 monthly faricimab injections as a loading dose and subsequently followed up at monthly intervals. All intravitreal injections were done in a sterile room and the second injection was treated as a separate procedure.</p><p><strong>Results: </strong>One hundred eyes from 50 patients were included in the study. The mean follow-up period was 7 months, during which a total of 487 intravitreal injections of faricimab were done. During the follow-up period, five patients (10%) presented with minor ophthalmic issues. There were no cases of endophthalmitis and no patients reported a cerebrovascular, cardiovascular, or thromboembolic event.</p><p><strong>Conclusions: </strong>Our study showed that bilateral same-day intravitreal injection of faricimab appeared to be well tolerated in this limited cohort and is the preferred approach in our practice. Larger studies with longer follow-up will be required in order to support our findings.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2055-2059"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy and Safety of Trabeculectomy after Failed Primary Glaucoma Drainage Devices.","authors":"Daniel Wang, Zhuangjun Si, Sanjay G Asrani, Joanne C Wen, Divakar Gupta","doi":"10.1007/s40123-025-01189-w","DOIUrl":"10.1007/s40123-025-01189-w","url":null,"abstract":"<p><strong>Introduction: </strong>Trabeculectomy is not usually considered for uncontrolled intraocular pressure (IOP) after glaucoma drainage devices (GDD) because of concern that the conjunctiva has been violated and future trabeculectomy surgery is likely to fail due to fibrosis. We examined the clinical outcomes of patients who underwent a trabeculectomy after failed primary GDD.</p><p><strong>Methods: </strong>This is a cross-sectional study of all patients who had a glaucoma drainage implant that failed or was inadequate in lowering IOP and underwent a trabeculectomy in the same eye from January 2016 to December 2022.</p><p><strong>Results: </strong>A total of 23 eyes in 22 patients met our criteria. Average IOP [± standard deviation (SD)] prior to trabeculectomy was 21.7 ± 9.3 on 3.2 ± 1.3 medications. The length of follow-up was between 0.3 and 5.0 years with an average follow-up time of 2.2 years. At 1 year (n = 16), IOP was 11 ± 1.9 mm Hg on 1.8 ± 1.5 medications. At 2 years, the average IOP was 11.8 ± 4.6 on 1.9 ± 1.4 medications. At all follow-up points, the decrease in IOP and medication was statistically significant compared with baseline (paired t-tests; p < 0.05). Most postoperative complications self-resolved with medical management (three early wound leaks, two late wound leaks, two instances of hypotony maculopathy, and one instance of cystoid macular edema). One early wound leak required surgical repair. One eye underwent an additional GDD surgery, and three eyes underwent bleb needling. In all, 20 (87%) eyes at final visit were within two lines of their baseline vision prior to trabeculectomy. No eyes progressed to having no light perception visual acuity or had an ocular infection.</p><p><strong>Conclusions: </strong>This study suggests that trabeculectomy after a GDD is an effective and safe option for IOP control and glaucoma medication reduction. In this small sample of surgical cases, complication and reoperation rates were comparable to published rates.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2061-2069"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous versus Intermittent Use of Tear Substitutes in Patients Treated with Anti-VEGF for Neovascular Age-Related Macular Degeneration: The TREDIA Study.","authors":"Héloïse Torres-Villaros, Audrey Giocanti-Aurégan, Serge Doan, Emilie Agard, Jérémy Billant, Nathalie Arbousoff, Benjamin Matagrin, Inès Fenniri, Corinne Dot","doi":"10.1007/s40123-025-01201-3","DOIUrl":"https://doi.org/10.1007/s40123-025-01201-3","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this prospective randomized bicenter study was to compare the effects of continuous versus intermittent use of tear substitutes on the ocular surface and dry eye symptoms in patients receiving repeated and frequent intravitreal injections (IVIs) for neovascular age-related macular degeneration (nAMD).</p><p><strong>Methods: </strong>Patients with nAMD treated with anti-vascular endothelial growth factor (anti-VEGF) for more than 1 year at 4-8-week intervals were included. The intermittent treatment group received standard 1.5% povidone artificial tears for three days after each IVI, while the continuous treatment group received an ophthalmic lubricant emulsion with 0.18% sodium hyaluronate four times a day throughout the study. The primary endpoint was the mean change in Ocular Surface Disease Index (OSDI) score between baseline and the day of the fourth IVI. Secondary endpoints included the Schirmer test score, tear break-up time (TBUT), and Oxford staining score.</p><p><strong>Results: </strong>Sixty-five patients with mean age of 83.1 ± 6.0 years who had previously received a mean number of 28.5 ± 20.3 IVIs were included. The mean OSDI score change from baseline was -6.6 ± 13.5 points in the continuous treatment group versus +0.6 ± 13.7 points in the intermittent treatment group (p = 0.04). No significant differences in Schirmer test score, TBUT, and Oxford score were found between the groups.</p><p><strong>Conclusions: </strong>Continuous use of tear substitutes in patients with nAMD receiving repeated and frequent IVIs could be beneficial in improving dry eye symptoms, as shown by a significant improvement in OSDI scores in our study, despite no substantial changes in other ocular surface metrics.</p><p><strong>Trial registration number: </strong>NCT06174181.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}